Xuzhou Medical Univ. V2R compound Peptide 33

Xuzhou Medical Univ. V2R compound Peptide 33: sourced facts only. name: "Peptide 33 exhibited a high binding affinity for the V2R (Ki = 6.1 ± 1.5 nM) and an extended residence time of 20 ± 1 min, 2-fold that of tolvaptan." [PMID:38509003]; target: "Peptide 33 exhibited a high binding affinity for the V2R (Ki = 6.1 ± 1.5 nM) and an extended residence time of 20 ± 1 min, 2-fold that of tolvaptan." [PMID:38509003]; developer: "Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, Jiangsu, China." [PMID:38509003]; modality: "Herein, we synthesized a set of peptide V2R antagonists." [PMID:38509003]; stage: "Furthermore, peptide 33 exhibited improved efficacies over tolvaptan in both ex vivo and in vivo models of ADPKD, underscoring its potential as a promising lead compound for the treatment of ADPKD." [PMID:38509003]